Established in 2000, Ningxia Tairui Pharmaceutical Co., Ltd. is a national high-tech enterprise. It is one of the 30 non-public dominant enterprises in the Ningxia Hui Autonomous Region. It has a national enterprise technology center, a national engineering laboratory, and nearly 3,500 employees. The total assets are nearly 5 billion, the bank's credit rating is AAA, and it has two subsidiaries and two branches. The company is mainly committed to the R&D, production and sales of raw materials, premixes and feed additives. Over the years, in the course of development, the company has continuously improved its own sales network and established a sales network centered on Beijing, covering more than 30 central cities and major international sales markets. Based on the domestic market, the company actively explores the international market, understands the dynamics of the international veterinary drug market, and strengthens the promotion of the international strategic brand of veterinary drugs. Since 2001, it has successively obtained the GMP certification of the Ministry of Agriculture, passed the quality audit certification of key enterprises in Poland, Germany, Belgium and other countries and regions, and is currently undergoing US FDA certification. The company has self-operated import and export rights, and more than 70% of its products are exported to foreign countries and exported to more than 80 countries and regions such as Brazil, India, and Germany. It is a key foreign exchange earning enterprise in the autonomous region and has a high international reputation and popularity. After more than ten years of market refinement and efficient operation, the company's products have rapidly developed from a single raw material to tylosin, tiamulin, tylosine, tilmicosin, premix, and other products, with production raw materials There are three dosage forms of medicine, premix and granule, and the production capacity of dozens of varieties. In 2007, the company entered the top 10 Chinese veterinary drug substance manufacturing enterprises, and won the titles of "China Outstanding Private Technology Enterprise" and "The Third Batch of Innovative Pilot Enterprises in China". In 2010, the Terry trademark was awarded the title of "China Famous Brand". At present, Terry Pharmaceutical has become China's largest veterinary raw material production base and export base, and the company's output value and sales revenue have been steadily increasing. In the future, the company will be dominated by differentiated competition and large-scale development, organically combine technological advantages, production capacity advantages and resource advantages, strive to achieve rapid development of the enterprise, and truly build our company into a world-class production scale bio-fermentation raw material The pharmaceutical production base will make greater contributions to the local economy of Ningxia and China's pharmaceutical andbiopharmaceutical businesses.